AU2015202975B2 — Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
Assigned to Vertex Pharmaceuticals Inc · Expires 2016-05-12 · 10y expired
What this patent protects
PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1 -(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1 -HYDROXY-2-METHYLPROPAN-2-YL)-1 H INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF A pharmaceutical composition comprising Compound , (R)-1-(2,2-dif…
USPTO Abstract
PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1 -(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1 -HYDROXY-2-METHYLPROPAN-2-YL)-1 H INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF A pharmaceutical composition comprising Compound , (R)-1-(2,2-difluorobenzo[d][1,3]dioxol 5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-IH-indol-5 yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound I are also disclosed.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.